S&P 500   4,594.63 (+0.59%)
DOW   36,245.50 (+0.82%)
QQQ   389.94 (+0.29%)
AAPL   191.24 (+0.68%)
MSFT   374.51 (-1.16%)
META   324.82 (-0.71%)
GOOGL   131.86 (-0.51%)
AMZN   147.03 (+0.64%)
TSLA   238.83 (-0.52%)
NVDA   467.65 (-0.01%)
NIO   7.16 (-1.51%)
BABA   73.98 (-1.20%)
AMD   121.39 (+0.19%)
T   16.77 (+1.21%)
F   10.58 (+3.02%)
MU   75.93 (-0.25%)
CGC   0.62 (+10.75%)
GE   122.50 (+0.57%)
DIS   92.55 (-0.15%)
AMC   6.87 (+3.16%)
PFE   28.91 (-5.12%)
PYPL   59.65 (+3.54%)
XOM   102.99 (+0.24%)
S&P 500   4,594.63 (+0.59%)
DOW   36,245.50 (+0.82%)
QQQ   389.94 (+0.29%)
AAPL   191.24 (+0.68%)
MSFT   374.51 (-1.16%)
META   324.82 (-0.71%)
GOOGL   131.86 (-0.51%)
AMZN   147.03 (+0.64%)
TSLA   238.83 (-0.52%)
NVDA   467.65 (-0.01%)
NIO   7.16 (-1.51%)
BABA   73.98 (-1.20%)
AMD   121.39 (+0.19%)
T   16.77 (+1.21%)
F   10.58 (+3.02%)
MU   75.93 (-0.25%)
CGC   0.62 (+10.75%)
GE   122.50 (+0.57%)
DIS   92.55 (-0.15%)
AMC   6.87 (+3.16%)
PFE   28.91 (-5.12%)
PYPL   59.65 (+3.54%)
XOM   102.99 (+0.24%)
S&P 500   4,594.63 (+0.59%)
DOW   36,245.50 (+0.82%)
QQQ   389.94 (+0.29%)
AAPL   191.24 (+0.68%)
MSFT   374.51 (-1.16%)
META   324.82 (-0.71%)
GOOGL   131.86 (-0.51%)
AMZN   147.03 (+0.64%)
TSLA   238.83 (-0.52%)
NVDA   467.65 (-0.01%)
NIO   7.16 (-1.51%)
BABA   73.98 (-1.20%)
AMD   121.39 (+0.19%)
T   16.77 (+1.21%)
F   10.58 (+3.02%)
MU   75.93 (-0.25%)
CGC   0.62 (+10.75%)
GE   122.50 (+0.57%)
DIS   92.55 (-0.15%)
AMC   6.87 (+3.16%)
PFE   28.91 (-5.12%)
PYPL   59.65 (+3.54%)
XOM   102.99 (+0.24%)
S&P 500   4,594.63 (+0.59%)
DOW   36,245.50 (+0.82%)
QQQ   389.94 (+0.29%)
AAPL   191.24 (+0.68%)
MSFT   374.51 (-1.16%)
META   324.82 (-0.71%)
GOOGL   131.86 (-0.51%)
AMZN   147.03 (+0.64%)
TSLA   238.83 (-0.52%)
NVDA   467.65 (-0.01%)
NIO   7.16 (-1.51%)
BABA   73.98 (-1.20%)
AMD   121.39 (+0.19%)
T   16.77 (+1.21%)
F   10.58 (+3.02%)
MU   75.93 (-0.25%)
CGC   0.62 (+10.75%)
GE   122.50 (+0.57%)
DIS   92.55 (-0.15%)
AMC   6.87 (+3.16%)
PFE   28.91 (-5.12%)
PYPL   59.65 (+3.54%)
XOM   102.99 (+0.24%)

Reviva Pharmaceuticals Stock Price, News & Analysis (NASDAQ:RVPH)

$3.84
0.00 (0.00%)
(As of 12/1/2023 ET)
Compare
Today's Range
$3.78
$3.99
50-Day Range
$3.71
$6.04
52-Week Range
$3.03
$9.25
Volume
229,605 shs
Average Volume
428,003 shs
Market Capitalization
$86.86 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$16.75

Reviva Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
336.8% Upside
$16.75 Price Target
Short Interest
Bearish
14.61% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.17mentions of Reviva Pharmaceuticals in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.51) to ($1.01) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.83 out of 5 stars

Medical Sector

716th out of 949 stocks

Pharmaceutical Preparations Industry

338th out of 442 stocks


RVPH stock logo

About Reviva Pharmaceuticals Stock (NASDAQ:RVPH)

Reviva Pharmaceuticals Holdings, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, cardiovascular, metabolic, and inflammatory diseases. The company's lead product candidate is brilaroxazine (RP5063), which is in Phase III clinical trials for the treatment of schizophrenia, as well as completed Phase I clinical trials to treat bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, Parkinson's disease psychosis, attention deficit hyperactivity disorder, pulmonary arterial hypertension, and idiopathic pulmonary fibrosis. It is also developing RP1208 that is in pre-clinical development studies for the treatment of depression and obesity. The company is based in Cupertino, California.

RVPH Stock Price History

RVPH Stock News Headlines

Trading Experts Call It “The Perfect Tesla Trade”
Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.
RVPH: Raise & RECOVER Results Review
Trading Experts Call It “The Perfect Tesla Trade”
Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.
Reviva Pharmaceuticals Holdings Inc Ordinary Shares
RVPH: RECOVER Topline
REVIVA PHARMACEUTICALS, INC.
See More Headlines
Receive RVPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Reviva Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/15/2021
Today
12/01/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
4/04/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:RVPH
Fax
N/A
Employees
10
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$16.75
High Stock Price Target
$20.00
Low Stock Price Target
$12.00
Potential Upside/Downside
+335.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-24,340,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
($0.38) per share

Miscellaneous

Free Float
15,441,000
Market Cap
$87.20 million
Optionable
Not Optionable
Beta
0.04
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report














RVPH Stock Analysis - Frequently Asked Questions

Should I buy or sell Reviva Pharmaceuticals stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Reviva Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" RVPH shares.
View RVPH analyst ratings
or view top-rated stocks.

What is Reviva Pharmaceuticals' stock price target for 2024?

4 brokerages have issued 1 year target prices for Reviva Pharmaceuticals' stock. Their RVPH share price targets range from $12.00 to $20.00. On average, they expect the company's stock price to reach $16.75 in the next year. This suggests a possible upside of 336.8% from the stock's current price.
View analysts price targets for RVPH
or view top-rated stocks among Wall Street analysts.

How have RVPH shares performed in 2023?

Reviva Pharmaceuticals' stock was trading at $4.25 at the beginning of the year. Since then, RVPH shares have decreased by 9.8% and is now trading at $3.8350.
View the best growth stocks for 2023 here
.

Are investors shorting Reviva Pharmaceuticals?

Reviva Pharmaceuticals saw a increase in short interest in the month of November. As of November 15th, there was short interest totaling 3,310,000 shares, an increase of 30.8% from the October 31st total of 2,530,000 shares. Based on an average daily volume of 1,100,000 shares, the short-interest ratio is presently 3.0 days.
View Reviva Pharmaceuticals' Short Interest
.

When is Reviva Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, April 4th 2024.
View our RVPH earnings forecast
.

How were Reviva Pharmaceuticals' earnings last quarter?

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) posted its quarterly earnings results on Monday, November, 15th. The company reported ($0.12) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.23) by $0.11.

Who are Reviva Pharmaceuticals' major shareholders?

Reviva Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include Armistice Capital LLC (2.65%), Silverarc Capital Management LLC (0.00%), Group One Trading L.P. (0.00%), EMC Capital Management (0.55%), Belvedere Trading LLC (0.00%) and GSA Capital Partners LLP (0.31%). Insiders that own company stock include Prabhu Narayan, Purav Patel and Vedanta Partners, Llc.
View institutional ownership trends
.

How do I buy shares of Reviva Pharmaceuticals?

Shares of RVPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:RVPH) was last updated on 12/1/2023 by MarketBeat.com Staff

My Account -